Reliance on third-party software vendors differentiates INC Research from its technology-investing peers but will not be a disadvantage, according to a Jefferies analyst.
As larger partnerships between CROs and sponsors come to maturity, a new survey found that “a much greater proportion of CRO revenue growth” will come from small and medium-sized pharma and biotech sponsor deals.
Covance has sold its high-complexity genomics laboratory to LabCorp as part of what an analyst says is decisive action to shed underperforming assets in its Early Development business.
New research suggests that – in general - strategic partnerships are working but CROs still need to improve on sponsors’ ‘high priority’ objectives or risk losing deals.
The US contract research organization (CRO) Quintiles may look at acquisitions and more ‘strategic partnerships’ after securing a $2.43bn credit facility.
